Sirtris Pharmaceuticals Presents at Future Leaders in the Biotechnology Industry Conference March 27
March 24 2008 - 7:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced that
it will be presenting at the BioCentury/Thomson Financial 15th
Annual Future Leaders in the Biotechnology Industry Conference on
Thursday, March 27 at 1:30 pm EDT. The presentation will be webcast
live and can be accessed on the Sirtris website
(www.sirtrispharma.com) in the "Investor Relations" section. A
replay will be available after the presentation and will be
archived on the company's website for two weeks. In January,
Sirtris announced positive Phase 1b clinical trial results with
drug candidate SRT501, a proprietary formulation of resveratrol, in
patients with Type 2 Diabetes. SRT501, which targets the SIRT1
enzyme, was found to be safe and well-tolerated, and significantly
lowered glucose at the two-hour time point in an oral glucose
tolerance test conducted as part of the 28 day Phase 1b trial of
patients with Type 2 Diabetes who were naive to treatment. Sirtris'
new chemical entities (NCEs) activate SIRT1 and are chemically
distinct from and 1000 times more potent, in vitro, than
resveratrol. The NCEs have been shown to lower glucose and improve
insulin sensitivity in predictive pre-clinical models of Type 2
Diabetes. SIRT1 activators have the potential to be a frontline
therapy for Type 2 Diabetes. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that the Company believes control the aging
process. The company's headquarters are in Cambridge,
Massachusetts. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, the potential therapeutic effects of SIRT1 activators including
NCEs for diseases of aging, such as Type 2 Diabetes: the progress
and results of pre-clinical and clinical studies of SIRT1
activators, such as SRT501 and Sirtris� NCEs; and the potential of
sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles